english.prescrire.org > Prescrire International > N°105 - February 2010

n°105

February 2010

Issue Contents
Editorial

Free  Enough is enough!

p.4
France's Health Authority must withdraw risky guidelines

New Products


Atomoxetine (attention-deficit/hyperactivity disorder)(New Drug)

p.5-8
No better than methylphenidate

Nicotinic acid + laropiprant (lipid disorders)(New Drug)

p.9-11
Adding laropiprant adds adverse effects

Dapoxetine (premature ejaculation)(New Drug)

p.12-14
Not worth the risk

INN common stem: -oxetine

p.14

Eltrombopag (Idiopathic thrombocytopenic purpura)(New Drug)

p.15
Romiplostim is a better option

Fentanyl sublingual tablets (breakthrough pain)(New Formulation)

p.16
No advantage

Adverse Effects


Benfluorex: increasing reports of valve disorders

p.17
News update: benfluorex withdrawn from the French market

Renal failure caused by drugs

p.18-21
Often predictable and preventable

Drug-induced cancer

p.21
Pharmacovigilance databases

Fentanyl patches: preventable overdose

p.22-25

Prescrire's advice

p.23
Preventing overdose with fentanyl transdermal patches

NSAIDs, ACE inhibitors, angiotensin II receptor antagonists, and isotretinoin: still too many pregnant women exposed French surveys

p.25

Cetirizine and loratadine: minimal risk of QT prolongation

p.26-28
Caution in some circumstances

Nasal corticosteroids: risk of systemic adverse effects

p.28
Lowest effective doses should be determined

Paediatric drug administration: frequent errors

p.28
Teach parents to use the INN, not the brand name

Free  Drug-induced memory disorders

p.29
Transient and reversible

Free  Carbimazole: cases of birth defects

p.29
Propylthiouracil a safer option during pregnancy

Reviews


Rheumatoid arthritis: choice of antirheumatic treatment

p.30-34
Methotrexate first

Preventing blindness due to diabetic retinopathy

p.35-38
Control glycaemia and blood pressure, and monitor the eyes

Diagnosis of fibrosis and cirrhosis

p.38-42
Liver biopsy is not always necessary

Outlook


Free  More clarity needed in funding of patient groups

p.43
Credibility is at stake

Free  Evaluation of treatment risks

p.44-45
Taking clinical data, pharmacology and patient characteristics into account

Free  Phase I trials

p.46
End the secrecy

Free  The 2010 "Prescrire Encounters" "For accessible quality healthcare" Brussels May 2010

p.48

Masthead


Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe